TY - JOUR
T1 - Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer
AU - Canto, Marcia Irene
AU - Kerdsirichairat, Tossapol
AU - Yeo, Charles J.
AU - Hruban, Ralph H.
AU - Shin, Eun Ji
AU - Almario, Jose Alejandro
AU - Blackford, Amanda
AU - Ford, Madeline
AU - Klein, Alison P.
AU - Javed, Ammar A.
AU - Lennon, Anne Marie
AU - Zaheer, Atif
AU - Kamel, Ihab R.
AU - Fishman, Elliot K.
AU - Burkhart, Richard
AU - He, Jin
AU - Makary, Martin
AU - Weiss, Matthew J.
AU - Schulick, Richard D.
AU - Goggins, Michael G.
AU - Wolfgang, Christopher L.
N1 - Funding Information:
CAPS 3 study participating centers and co-investigators (listed in alphabetical order) Dana Farber Cancer Institute, Boston, MA (Koenraad Mortele, John Saltzman, Sapna Syngal); The Mayo Clinic, Rochester, MN (Joel Fletcher, Gloria Petersen, Naoki Takahashi, Mark Topazian), MD Anderson Cancer Center, Houston, TX (Priya Bosale, Jeffrey Lee, Eric Tamm, Raghunandan Vikram), and University of California, Los Angeles, CA (James Farrell, Daniel Margolis).
Publisher Copyright:
© 2019, The Society for Surgery of the Alimentary Tract.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Background: Screening high-risk individuals (HRI) can detect potentially curable pancreatic ductal adenocarcinoma (PDAC) and its precursors. We describe the outcomes of high-risk individuals (HRI) after pancreatic resection of screen-detected neoplasms. Methods: Asymptomatic HRI enrolled in the prospective Cancer of the Pancreas Screening (CAPS) studies from 1998 to 2014 based on family history or germline mutations undergoing surveillance for at least 6 months were included. Pathologic diagnoses, hospital length of stay, incidence of diabetes mellitus, operative morbidity, need for repeat operation, and disease-specific mortality were determined. Results: Among 354 HRI, 48 (13.6%) had 57 operations (distal pancreatectomy (31), Whipple (20), and total pancreatectomy (6)) for suspected pancreatic neoplasms presenting as a solid mass (22), cystic lesion(s) (25), or duct stricture (1). The median length of stay was 7 days (IQR 5–11). Nine of the 42 HRI underwent completion pancreatectomy for a new lesion after a median of 3.8 years (IQR 2.5–7.6). Postoperative complications developed in 17 HRI (35%); there were no perioperative deaths. New-onset diabetes mellitus after partial resection developed in 20% of HRI. Fourteen PDACs were diagnosed, 11 were screen-detected, 10 were resectable, and 9 had an R0 resection. Metachronous PDAC developed in remnant pancreata of 2 HRI. PDAC-related mortality was 4/10 (40%), with 90% 1-year survival and 60% 5-year survival, respectively. Conclusions: Screening HRI can detect PDAC with a high resectability rate. Surgical treatment is associated with a relatively short length of stay and low readmission rate, acceptable morbidity, zero 90-day mortality, and significant long-term survival.
AB - Background: Screening high-risk individuals (HRI) can detect potentially curable pancreatic ductal adenocarcinoma (PDAC) and its precursors. We describe the outcomes of high-risk individuals (HRI) after pancreatic resection of screen-detected neoplasms. Methods: Asymptomatic HRI enrolled in the prospective Cancer of the Pancreas Screening (CAPS) studies from 1998 to 2014 based on family history or germline mutations undergoing surveillance for at least 6 months were included. Pathologic diagnoses, hospital length of stay, incidence of diabetes mellitus, operative morbidity, need for repeat operation, and disease-specific mortality were determined. Results: Among 354 HRI, 48 (13.6%) had 57 operations (distal pancreatectomy (31), Whipple (20), and total pancreatectomy (6)) for suspected pancreatic neoplasms presenting as a solid mass (22), cystic lesion(s) (25), or duct stricture (1). The median length of stay was 7 days (IQR 5–11). Nine of the 42 HRI underwent completion pancreatectomy for a new lesion after a median of 3.8 years (IQR 2.5–7.6). Postoperative complications developed in 17 HRI (35%); there were no perioperative deaths. New-onset diabetes mellitus after partial resection developed in 20% of HRI. Fourteen PDACs were diagnosed, 11 were screen-detected, 10 were resectable, and 9 had an R0 resection. Metachronous PDAC developed in remnant pancreata of 2 HRI. PDAC-related mortality was 4/10 (40%), with 90% 1-year survival and 60% 5-year survival, respectively. Conclusions: Screening HRI can detect PDAC with a high resectability rate. Surgical treatment is associated with a relatively short length of stay and low readmission rate, acceptable morbidity, zero 90-day mortality, and significant long-term survival.
KW - Early detection
KW - Pancreatic cancer
KW - Screening
KW - Surgical outcomes
UR - http://www.scopus.com/inward/record.url?scp=85067693364&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067693364&partnerID=8YFLogxK
U2 - 10.1007/s11605-019-04230-z
DO - 10.1007/s11605-019-04230-z
M3 - Article
C2 - 31197699
AN - SCOPUS:85067693364
SN - 1091-255X
VL - 24
SP - 1101
EP - 1110
JO - Journal of Gastrointestinal Surgery
JF - Journal of Gastrointestinal Surgery
IS - 5
ER -